Cannabis Rescheduling and Implications for Financial Institutions

Today, the U.S. Department of Justice (DOJ) took a meaningful and necessary step in formally acknowledging and supporting the medical use of cannabis in the United States. In issuing its final rescheduling order, the DOJ was tasked with balancing domestic federal law alongside the United States’ international treaty obligations. While that balance was not without constraint, the result represents a significant and constructive development for state regulated medical cannabis programs.

At the same time, the DOJ’s approach has clearly—and deliberately—separated state medical marijuana programs from state adult use (recreational) programs under federal law. This distinction is now sharper than at any previous point in federal cannabis policy.

Implications for Medical Marijuana Programs

For state-licensed medical cannabis operators, this action is meaningfully positive. The DOJ has:

• Acknowledged the integrity of existing state medical licensing frameworks,

• Established a pathway for federal registration that relies heavily on those state systems, and

• Recognized the resulting federal tax implications, including explicitly encouraging the Internal Revenue Service to consider retroactive relief from Section 280E for medical licensees.

This represents a strong federal signal that well-regulated medical programs are legitimate, enduring, and worthy of regulatory accommodation, even within the boundaries imposed by international scheduling requirements.

Implications for Adult-Use Programs

For adult use cannabis, the practical outcome is more limited. While we do not expect a material shift in federal prosecution priorities for compliant, state licensed adult use programs, much of the relief addressed in the DOJ’s order does not extend to non-medical activity.

Adult use cannabis remains federally illegal, subject to Schedule I treatment, and outside the scope of the rescheduling action.

In short, this order does not signal an enforcement crackdown on adult use markets—but it also does not resolve the longstanding federal state disconnect affecting those programs.

What this Action Does NOT Do

• Legalize marijuana at the federal level,

• Change the federal status of adult use (recreational) cannabis,

• Alter interstate commerce restrictions,

• Modify Bank Secrecy Act or AML statutes,

• Issue new FinCEN guidance, or

• Provide safe harbor for payment networks or credit card rails.

Any changes in those areas would require separate regulatory action or congressional legislation, which DOJ explicitly notes are outside the scope of this order.

Acting Attorney General Todd Blanche said he plans to order a new hearing “to fully reschedule marijuana.” The hearing, which aims to “provide a timely and legally compliant pathway to evaluate broader changes to marijuana’s status under federal law,” is set to begin on June 29 and conclude no later than July 15, 2026.

Our Call to Action for Bankers

Financial institutions should view this moment as an inflection point and begin thoughtfully evaluating how their cannabis banking policies may evolve, including:

• Whether to maintain medical only programs, adult use programs, or both;

• How to stay closely aligned with state rule changes, particularly as states adapt medical frameworks in response to the federal shift; and

• How to manage heightened complexity in states where medical and adult use markets are interoperable, shared, or operationally intertwined.

• Importantly, Bank Secrecy Act obligations remain largely unchanged at this time. However, consistent with how regulatory expectations evolved following the legalization of hemp, we anticipate a gradual differentiation in supervisory posture:

• Medical marijuana programs are likely to remain classified as high-risk, but with increasingly standardized oversight, monitoring, and filing expectations aligned to other regulated, high risk industries.

• Adult use cannabis programs will continue to fall under the 2014 FinCEN guidance, including the existing SAR framework and heightened scrutiny.

Call for Continued Federal Action

Shield Compliance encourages FinCEN to issue updated guidance reflecting this new federal landscape, particularly to help financial institutions responsibly distinguish between medical and adult use risk profiles.

We also underscore to Congress that legislative solutions such as SAFER Banking and the CLIMB Act remain essential. The DOJ’s action—by its own design—operates within the constraints of federal scheduling law. Durable, comprehensive reform will ultimately require congressional action to resolve the remaining structural barriers affecting both financial institutions and state regulated cannabis businesses.